DE60138115D1 - Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind - Google Patents

Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind

Info

Publication number
DE60138115D1
DE60138115D1 DE60138115T DE60138115T DE60138115D1 DE 60138115 D1 DE60138115 D1 DE 60138115D1 DE 60138115 T DE60138115 T DE 60138115T DE 60138115 T DE60138115 T DE 60138115T DE 60138115 D1 DE60138115 D1 DE 60138115D1
Authority
DE
Germany
Prior art keywords
heparine
molecular
low
products associated
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138115T
Other languages
English (en)
Inventor
Mallikarjum Sundaram
Ganesh Venkataraman
Zachary Shriver
Dongfang Liu
Yi Wei Qi
Ram Sasisekharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of DE60138115D1 publication Critical patent/DE60138115D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
DE60138115T 2000-09-12 2001-09-12 Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind Expired - Lifetime DE60138115D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23199400P 2000-09-12 2000-09-12
PCT/US2001/028457 WO2002023190A2 (en) 2000-09-12 2001-09-12 Methods and products related to low molecular weight heparin

Publications (1)

Publication Number Publication Date
DE60138115D1 true DE60138115D1 (de) 2009-05-07

Family

ID=22871450

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138115T Expired - Lifetime DE60138115D1 (de) 2000-09-12 2001-09-12 Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind

Country Status (12)

Country Link
US (6) US7083937B2 (de)
EP (2) EP2085780B1 (de)
JP (2) JP4911865B2 (de)
AT (1) ATE426805T1 (de)
AU (1) AU2001292618A1 (de)
CA (1) CA2422059C (de)
CY (1) CY1110323T1 (de)
DE (1) DE60138115D1 (de)
DK (1) DK1319183T3 (de)
ES (2) ES2640975T3 (de)
PT (1) PT1319183E (de)
WO (1) WO2002023190A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527822A (ja) 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ
CA2370539C (en) * 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
AU4351201A (en) * 2000-03-08 2001-09-17 Massachusetts Inst Technology Heparinase iii and uses thereof
ATE426805T1 (de) 2000-09-12 2009-04-15 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
AU2002362903A1 (en) * 2001-10-16 2003-04-28 Procognia, Ltd. Method of preparing purified biologically active oligosaccharide libraries
EP1518120A4 (de) 2002-03-11 2008-08-13 Momenta Pharmaceuticals Inc Analyse sulfatierter polysaccharide
WO2003090696A2 (en) * 2002-04-25 2003-11-06 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
EP1575534B1 (de) * 2002-05-03 2013-04-10 Massachusetts Institute Of Technology D4,5 glycuronidase und ihre verwendungen
WO2004055491A2 (en) * 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
EP1532241B1 (de) * 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
DE10315581B4 (de) 2003-04-05 2007-06-28 Agilent Technologies, Inc. (n.d.Ges.d.Staates Delaware), Palo Alto Verfahren zur Qualitätsbestimmung von RNA-Proben
CN1886427B (zh) 2003-11-28 2012-05-23 伊士曼化工公司 纤维素共聚体和氧化方法
US7507570B2 (en) 2004-03-10 2009-03-24 Massachusetts Institute Of Technology Recombinant chondroitinase ABC I and uses thereof
WO2005111627A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US8101244B2 (en) 2004-06-09 2012-01-24 Smithkline Beecham Corporation Apparatus and method for producing or processing a product or sample
TWI356036B (en) 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
US20060002594A1 (en) * 2004-06-09 2006-01-05 Clarke Allan J Method for producing a pharmaceutical product
CA2614068A1 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
DE102005038418A1 (de) * 2005-08-12 2007-02-15 Dade Behring Marburg Gmbh Faktor Xa-basierter Heparinassay unter Verwendung einer Heparin-modifizierenden Komponente
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
EP2008096A2 (de) * 2006-04-03 2008-12-31 Massachusetts Institute of Technology Glykomische muster für den nachweis von erkrankungen
EP2019843A2 (de) 2006-05-25 2009-02-04 Momenta Pharmaceuticals, Inc. Heparin-zusammensetzung mit geringem molekulargewicht und anwendungen davon
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
WO2008085912A1 (en) * 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) * 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
AU2010328726B2 (en) * 2009-12-09 2017-01-19 Agency For Science, Technology And Research Glycosaminoglycan mixtures
WO2011090948A1 (en) 2010-01-19 2011-07-28 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
JP5645493B2 (ja) * 2010-06-15 2014-12-24 川崎重工業株式会社 多糖類検査装置および多糖類検査方法
EP2598652A4 (de) 2010-07-29 2014-04-30 Shire Human Genetic Therapies Tests zum nachweis von glykosaminoglykanen
AU2015203727B2 (en) * 2010-09-14 2016-05-26 Fuso Pharmaceutical Industries, Ltd. High Purity Heparin and Production Method Therefor
DK2617737T3 (en) * 2010-09-14 2017-04-03 Univ Miyazaki HIGH PURPOSE HEPARIN AND PREPARATION PROCEDURE
UA112070C2 (uk) * 2011-01-28 2016-07-25 Хангжоу Джіуюан Джін Енджініерінг Ко., Лтд Спосіб капілярного електрофорезу для аналізу тонкої структури еноксапарину натрію
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
ES2656613T3 (es) * 2011-12-19 2018-02-27 Dilafor Ab Glicosaminoglicanos no anticoagulantes que comprenden unidades de repetición de disacáridos y su uso médico
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
WO2013116677A2 (en) * 2012-02-01 2013-08-08 Shire Human Genetic Therapies, Inc. Assays for detection of glycosaminoglycans
ES2445494B1 (es) * 2012-08-02 2015-03-06 Rovi Lab Farmaceut Sa Procedimiento de obtención de heparinas de bajo y muy bajo peso molecular
CA3144968A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
CN111019014A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种那曲肝素钙的制备工艺
EP4182452A1 (de) 2020-07-14 2023-05-24 Optimvia, LLC Verfahren zur synthese von nicht-antikoagulierendem heparansulfat
CN114264741B (zh) * 2021-12-15 2022-08-19 山东大学 一种鉴别猪来源肝素是否掺反刍类动物肝素的方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1390633A (en) * 1921-06-17 1921-09-13 Edgar A Milhaupt Bumper-bracket
US4281108A (en) 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
US4443545A (en) 1980-08-25 1984-04-17 Massachusetts Institute Of Technology Process for producing heparinase
US4341869A (en) 1980-08-25 1982-07-27 Massachusetts Institute Of Technology Process for producing heparinase
US4373023A (en) 1980-10-14 1983-02-08 Massachusetts Institute Of Technology Process for neutralizing heparin
US4396762A (en) 1981-08-24 1983-08-02 Massachusetts Institute Of Technology Heparinase derived anticoagulants
US4551296A (en) 1982-03-19 1985-11-05 Allied Corporation Producing high tenacity, high modulus crystalline article such as fiber or film
FR2554348B1 (fr) 1983-11-04 1987-01-23 Tissier Gerard Complexes hepariniques marques au moyen de radio-elements de vie courte emetteurs de radiations non ionisantes, leur procede d'obtention, les produits intermediaires et application de ces complexes
US4757056A (en) 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
US4679555A (en) 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US5106734A (en) 1986-04-30 1992-04-21 Novo Nordisk A/S Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin
DK196986D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
US4942156A (en) 1986-08-20 1990-07-17 Hepar Industries, Inc. Low molecular weight heparin derivatives having improved anti-Xa specificity
US4745105A (en) 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US4830013A (en) 1987-01-30 1989-05-16 Minnesota Mining And Manufacturing Co. Intravascular blood parameter measurement system
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
US5169772A (en) 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
IT1234508B (it) 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
GB8826448D0 (en) 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
CA1340966C (en) 1989-05-19 2000-04-18 Thomas R. Covey Method of protein analysis
IT1237518B (it) 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5152784A (en) 1989-12-14 1992-10-06 Regents Of The University Of Minnesota Prosthetic devices coated with a polypeptide with type IV collagen activity
US5284558A (en) 1990-07-27 1994-02-08 University Of Iowa Research Foundation Electrophoresis-based sequencing of oligosaccharides
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
JP3110064B2 (ja) 1991-03-06 2000-11-20 生化学工業株式会社 新規ヘパリチナーゼ、その製造法及びその生産菌
US5262325A (en) 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
CA2102207A1 (en) 1991-05-02 1992-11-03 Irun R. Cohen Compositions for the prevention and/or treatment of patholigical processes
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
EP0641438A1 (de) 1991-11-21 1995-03-08 Glyko, Inc. Fluorophor-unterstirte kontrolle medikamentoser therapien
GB9202019D0 (en) 1992-01-30 1992-03-18 Imperial College Methods and apparatus for assay of sulphated polysaccharides
IT1254216B (it) 1992-02-25 1995-09-14 Opocrin Spa Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
US5453171A (en) 1992-03-10 1995-09-26 The Board Of Regents Of The University Of Michigan Heparin-selective polymeric membrane electrode
US5856928A (en) 1992-03-13 1999-01-05 Yan; Johnson F. Gene and protein representation, characterization and interpretation process
GB9206291D0 (en) 1992-03-23 1992-05-06 Cancer Res Campaign Tech Oligosaccharides having growth factor binding affinity
WO1993019734A1 (en) 1992-04-02 1993-10-14 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
GB9306255D0 (en) 1993-03-25 1993-05-19 Cancer Res Campaign Tech Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity
FR2704861B1 (fr) 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US7005510B1 (en) * 1993-06-23 2006-02-28 Beckman Instruments, Inc. Recombinant DNase B derived from Streptococcus pyogenes
WO1995013830A1 (en) 1993-11-17 1995-05-26 Massachusetts Institute Of Technology Method for inhibiting angiogenesis using heparinase
US6013628A (en) 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US6376196B1 (en) * 1996-05-10 2002-04-23 The Regents Of The University Of California Recombinant neospora antigens and their uses
US5607859A (en) 1994-03-28 1997-03-04 Massachusetts Institute Of Technology Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
WO1995030424A1 (en) 1994-05-06 1995-11-16 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5619421A (en) 1994-06-17 1997-04-08 Massachusetts Institute Of Technology Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723847A1 (fr) 1994-08-29 1996-03-01 Debiopharm Sa Compositions antithrombotiques et non hemorragiques a base d'heparine, procede pour leur preparation et applications therapeutiques.
US5687090A (en) 1994-09-01 1997-11-11 Aspen Technology, Inc. Polymer component characterization method and process simulation apparatus
AU700903B2 (en) 1994-10-12 1999-01-14 Focal, Inc. Targeted delivery via biodegradable polymers
US5569366A (en) * 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis
US5618917A (en) 1995-02-15 1997-04-08 Arch Development Corporation Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US5763427A (en) 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
JP3318578B2 (ja) 1995-05-26 2002-08-26 サーモディックス，インコーポレイティド 内皮化を促進するための方法及び移植用製品
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5690910A (en) 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5752019A (en) 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
DK0896525T3 (da) 1996-04-29 2003-12-01 Quadrant Technologies Ltd Fremgangsmåder til tørpulverinhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU3892297A (en) 1996-07-26 1998-02-20 Ikonos Corporation Sensor for detecting heparin and other analytes
WO1998005920A1 (en) * 1996-08-08 1998-02-12 William Marsh Rice University Macroscopically manipulable nanoscale devices made from nanotube assemblies
US5759767A (en) 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
PT954282E (pt) 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6190875B1 (en) * 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US6268146B1 (en) 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
JP2003527822A (ja) 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ
US6291439B1 (en) * 1998-09-02 2001-09-18 Biomarin Pharmaceuticals Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
CA2370539C (en) * 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
AU4351201A (en) 2000-03-08 2001-09-17 Massachusetts Inst Technology Heparinase iii and uses thereof
JP4889902B2 (ja) * 2000-03-14 2012-03-07 イーエス・セル・インターナショナル・プライヴェート・リミテッド ヒト胚性幹（ｈＥＳ）細胞からヒト神経前駆細胞を作製する方法、並びに、該方法を利用したニューロンの作製方法、稀突起膠細胞又は星状細胞の作製方法
US6373194B1 (en) * 2000-06-01 2002-04-16 Raytheon Company Optical magnetron for high efficiency production of optical radiation
ATE426805T1 (de) * 2000-09-12 2009-04-15 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US6777244B2 (en) * 2000-12-06 2004-08-17 Hrl Laboratories, Llc Compact sensor using microcavity structures
US20020071457A1 (en) * 2000-12-08 2002-06-13 Hogan Josh N. Pulsed non-linear resonant cavity
CA2441986A1 (en) 2001-03-27 2002-10-03 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
US6788847B2 (en) * 2001-04-05 2004-09-07 Luxtera, Inc. Photonic input/output port
US7248297B2 (en) * 2001-11-30 2007-07-24 The Board Of Trustees Of The Leland Stanford Junior University Integrated color pixel (ICP)
EP1471828A1 (de) * 2002-01-18 2004-11-03 California Institute Of Technology Verfahren und gerät für die nanomagnetische manipulation und messung
EP1575534B1 (de) 2002-05-03 2013-04-10 Massachusetts Institute Of Technology D4,5 glycuronidase und ihre verwendungen
WO2004055491A2 (en) 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
EP1532241B1 (de) 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
US6887773B2 (en) * 2002-06-19 2005-05-03 Luxtera, Inc. Methods of incorporating germanium within CMOS process
US8228959B2 (en) * 2002-09-27 2012-07-24 The Trustees Of Dartmouth College Free electron laser, and associated components and methods
US6922118B2 (en) * 2002-11-01 2005-07-26 Hrl Laboratories, Llc Micro electrical mechanical system (MEMS) tuning using focused ion beams
JP4606712B2 (ja) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
US7141800B2 (en) * 2003-07-11 2006-11-28 Charles E. Bryson, III Non-dispersive charged particle energy analyzer
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
US7851223B2 (en) 2004-02-27 2010-12-14 Roar Holding Llc Method to detect emphysema
US7507570B2 (en) 2004-03-10 2009-03-24 Massachusetts Institute Of Technology Recombinant chondroitinase ABC I and uses thereof
EP1582531A1 (de) * 2004-03-24 2005-10-05 Aventis Pharma S.A. Verfahren zur Oxydierung nicht-fraktionierten Heparins und die Detektion der Anwesenheit oder Abwesenheit von Glykoserin in Heparin und in von Heparin abgeleiteten Produkten
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US7586097B2 (en) * 2006-01-05 2009-09-08 Virgin Islands Microsystems, Inc. Switching micro-resonant structures using at least one director
US20060154894A1 (en) 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
US20060187794A1 (en) * 2004-10-14 2006-08-24 Tim Harvey Uses of wave guided miniature holographic system
WO2006076627A2 (en) 2005-01-12 2006-07-20 Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
WO2006089206A2 (en) 2005-02-16 2006-08-24 Massachusetts Institute Of Technology Methods to enhance carbon monoxide dehydrogenase activity and uses thereof
US20090105463A1 (en) * 2005-03-29 2009-04-23 Massachusetts Institute Of Technology Compositions of and Methods of Using Oversulfated Glycosaminoglycans
US20090156477A1 (en) * 2005-03-29 2009-06-18 Massachusetts Institute Of Technology Compositions and Methods for Regulating Inflammatory Responses
US7619373B2 (en) * 2006-01-05 2009-11-17 Virgin Islands Microsystems, Inc. Selectable frequency light emitter
EP2008096A2 (de) * 2006-04-03 2008-12-31 Massachusetts Institute of Technology Glykomische muster für den nachweis von erkrankungen
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum

Also Published As

Publication number Publication date
EP2085780A3 (de) 2011-08-17
PT1319183E (pt) 2009-06-29
US20060024664A1 (en) 2006-02-02
JP4911865B2 (ja) 2012-04-04
WO2002023190A2 (en) 2002-03-21
EP1319183B1 (de) 2009-03-25
EP1319183A2 (de) 2003-06-18
US7399604B2 (en) 2008-07-15
EP2085780B1 (de) 2017-06-21
AU2001292618A1 (en) 2002-03-26
ES2324701T3 (es) 2009-08-13
DK1319183T3 (da) 2009-05-18
JP2004509339A (ja) 2004-03-25
WO2002023190A3 (en) 2003-03-13
US7687479B2 (en) 2010-03-30
CA2422059C (en) 2012-05-15
US20130017565A1 (en) 2013-01-17
US8173384B2 (en) 2012-05-08
US8512969B2 (en) 2013-08-20
US20070161073A1 (en) 2007-07-12
US20100062468A1 (en) 2010-03-11
US20070065921A1 (en) 2007-03-22
US7083937B2 (en) 2006-08-01
US7585642B2 (en) 2009-09-08
JP2011169913A (ja) 2011-09-01
ES2640975T3 (es) 2017-11-07
JP5186019B2 (ja) 2013-04-17
WO2002023190A8 (en) 2011-10-27
CY1110323T1 (el) 2014-02-12
CA2422059A1 (en) 2002-03-21
US20020169143A1 (en) 2002-11-14
ATE426805T1 (de) 2009-04-15
EP2085780A2 (de) 2009-08-05

Similar Documents

Publication Publication Date Title
DE60138115D1 (de) Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
DE69015964D1 (de) Verfahren und Zusammensetzungen, die bestimmte Lysozyme und Endoglycosidase verwenden.
NL194947B (nl) Mengsels van polysacchariden met laag molecuulgewicht en werkwijze voor de bereiding ervan, en de toepassing ervan.
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
AU2001240915A1 (en) Methods of accessing and using web-pages
WO1991005754A3 (fr) Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophiques et cytoprotectrices, et compositions pharmaceutiques les contenant
DE69524977D1 (de) Lösliche, elektroleitfähige polypyrrole und verfahren zur herstellung
DE69330226D1 (de) Geliermittel auf Basis von Xanthan
ITCO990031A0 (it) Metodo ed apparecchiatura per la produzione di articoli tridimensional i di maglieria e calzetteria e prodotti risultanti.
DE68914638T2 (de) Polyaluminosilikat-mikrogel, verfahren und zusammensetzung.
DE68923171D1 (de) Aluminiumhydroxyd, verfahren zur herstellung und zusammensetzung.
DE69616852D1 (de) Feuchthaltemittel, antistatisches Mittel, Dispergiermittel und filmbildendes Mittel mit Polysaccharid als wirksames Prinzip; Verfahren zur Herstellung von Polysacchariden und Klebsiella Stamm
ITBO920440A1 (it) Metodo per la produzione di prodotti, in particolare articoli da fumo
DE69124844D1 (de) Radicicol-Derivate, ihre Herstellung und ihre Antitumorwirkung
DE69842088D1 (de) Nukleinsäureleitern
IT1314768B1 (it) Processo per la produzione di additivi antifiamma per composizionipolimeriche,e prodotti ottenuti da detto processo
DE3769358D1 (de) 1-acyl-2,3-dihydro-4(1h)-chinolinon-4-oxim-derivate, verfahren zur herstellung davon, pharmazeutische zusammensetzungen und zwischenprodukte.
AU3424095A (en) Method of manufacturing non-absorbable synthetic sulfated polysaccharides
DE69519564D1 (de) Verfahren zur herstellung von 4,4-dialkyl-6-halogen-chromanen oder -thiochromanen, welche als pharmazeutische zwischenprodukte brauchbar sind
ATE397615T1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
IT1302971B1 (it) Procedimento di produzione per prosciutti, e mezzi relativi alprocedimento
WO2003033512A3 (en) Method of preparing purified biologically active oligosaccharide libraries
IT1293686B1 (it) Metodo e macchina per la produzione di articoli di vetro.
ATE104252T1 (de) Polyaluminosilikat-mikrogel, verfahren und zusammensetzung.
DE69925916D1 (de) Immunstimulierende Phellinus ssp. Polysaccharid und Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition